| Drug General Information |
| Drug ID |
D0K4MH
|
| Former ID |
DNAP001696
|
| Drug Name |
Tapentadol hydrochloride
|
| Drug Type |
Small molecular drug
|
| Indication |
Moderate-to-severe acute pain [ICD9: 338,780; ICD10:R52, G89]
|
Approved |
[1]
|
|---|
| Company |
Ortho-McNell Pharmaceutical
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C14H23NO
|
| Canonical SMILES |
CCC(C1=CC(=CC=C1)O)C(C)CN(C)C
|
| InChI |
1S/C14H23NO/c1-5-14(11(2)10-15(3)4)12-7-6-8-13(16)9-12/h6-9,11,14,16H,5,10H2,1-4H3/t11-,14+/m0/s1
|
| InChIKey |
KWTWDQCKEHXFFR-SMDDNHRTSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
14892326, 24136893, 44936111, 47207665, 50598570, 57373488, 87692438, 124772162, 126644483, 126666948, 128445985, 135207317, 135693229, 135693230, 136980026, 137147726, 142418252, 144115428, 152090609, 160693267, 160865464, 162012004, 164041986, 172919383, 174527899, 175267498, 175427057, 179150074, 187051780, 210276624, 223519387, 223661873, 224282350, 226489097, 252481185
|
| SuperDrug ATC ID |
N02AX06
|
| Target and Pathway |
| Target(s) |
Mu-type opioid receptor |
Target Info |
Modulator |
[1]
|
|---|
| Sodium-dependent noradrenaline transporter |
Target Info |
Modulator |
[1]
|
|
KEGG Pathway
|
Neuroactive ligand-receptor interaction
|
|
Estrogen signaling pathway
|
|
Morphine addiction
|
|
NetPath Pathway
|
TCR Signaling Pathway
|
|
PANTHER Pathway
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
|
Enkephalin releaseP00001:Adrenaline and noradrenaline biosynthesis
|
|
Pathway Interaction Database
|
IL4-mediated signaling events
|
|
Reactome
|
Peptide ligand-binding receptors
|
|
G alpha (i) signalling eventsR-HSA-442660:Na+/Cl- dependent neurotransmitter transporters
|
|
WikiPathways
|
TCR Signaling Pathway
|
|
GPCRs, Class A Rhodopsin-like
|
|
Peptide GPCRs
|
|
Opioid Signalling
|
|
GPCR ligand binding
|
|
GPCR downstream signalingWP727:Monoamine Transport
|
|
NRF2 pathway
|
|
Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds
|
| References |
| REF 1 | 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. |
|---|
